Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration

Retina

Volumn 35, Issue 5, 2015, Pages 975-981

  Broadhead, Geoffrey K ^a,b   Hong, Thomas ^a   Zhu, Meidong ^a,b   Li, Haitao ^a   Schlub, Timothy E ^c   Wijeyakumar, Wijeyanthy ^a,b   Chang, Andrew A ^a,b  

^a Sydney Retina Clinic   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

aflibercept; neovascular age related macular degeneration; pigment epithelial detachment

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEIGHT; HUMAN; LENGTH; LOADING DRUG DOSE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA TEAR; TREATMENT DURATION; TREATMENT RESISTANT NEOVASCULAR AGE RELATED MACULAR DEGENERATION; TREATMENT RESPONSE; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; DRUG EFFECTS; DRUG RESISTANCE; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; PATHOLOGY; PIGMENT EPITHELIUM; RETINAL DETACHMENT; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; DRUG RESISTANCE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84929049456     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000409     Document Type: Article

References (19)

1. Holz FG, Pauleikhoff D, Klein R, Bird AC. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 2004;137:504-510.
2. Mrejen S, Sarraf D, Mukkamala SK, Freund KB. Multimodal imaging of pigment epithelial detachment: a guide to evaluation. Retina 2013;33:1735-1762.
3. Doguizi S, Ozdek S. Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration. Retina 2014;34:1156-1162.
4. Patel KH, Chow CC, Rathod R, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013;27:663-667; quiz 668.
5. Keane PA, Heussen FM, Ouyang Y, et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2012;53:1152-1161.
6. Parodi MB, Iacono P, Papayannis A, et al. Intravitreal ranibizumab for pigment epithelial detachment with subfoveal occult neovascularization: a prospective 24-month case series. Am J Ophthalmol 2013;155:103-108.
7. Punjabi OS, Huang J, Rodriguez L, et al. Imaging characteristics of neovascular pigment epithelial detachments and their response to anti-vascular endothelial growth factor therapy. Br J Ophthalmol 2013;97:1024-1031.
8. Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol 2009;147:644-652.
9. Ying GS, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-129.
10. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012;119:2537-2548.
11. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF trap. Br J Ophthalmol 2008;92:667-668.
12. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-185.
13. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013;33:1605-1612.
14. Chang AA, Li H, Broadhead GK, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 2014;121:188-192.
15. Panos GD, Gatzioufas Z, Petropoulos IK, et al. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration. Drug Des Devel Ther 2013;7:565-569.
16. Ach T, Hoeh AE, Ruppenstein M, et al. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Retina 2010;30:1420-1425.
17. Arora S, McKibbin M. One-year outcome after intravitreal ranibizumab for large, serous pigment epithelial detachment secondary to age-related macular degeneration. Eye (Lond) 2011;25:1034-1038.
18. Introini U, Torres Gimeno A, Scotti F, et al. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence. Graefes Arch Clin Exp Ophthalmol 2012;250:1283-1292.
19. Cunningham ET Jr, Feiner L, Chung C, et al. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. Ophthalmology 2011;118:2447-2452.